Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility
Irene Catucci(IFOM), Paolo Peterlongo(IFOM), Therese Törngren(Lund University), Mirko Riboni(IFOM), Hans Ehrencrona(Lund University), Jacopo Azzollini(Fondazione IRCCS Istituto Nazionale dei Tumori), Siranoush Manoukian(Fondazione IRCCS Istituto Nazionale dei Tumori), Federica Zanardi(IFOM), Guido Neidhardt(University of Cologne), Ana Osório(Spanish National Cancer Research Centre), Stefano Casola(IFOM), Javier Benı́tez(Spanish National Cancer Research Centre), Simone P. Minardi(IFOM), Anders Kvist(Lund University), Jan Hauke(University Hospital Cologne), Eric Hahnen(University Hospital Cologne), Bernard Peissel(Sapienza University of Rome), Jordi Surrallés(Universitat Autònoma de Barcelona), Lisa Richters(University of Cologne), Massimo Bogliolo(Universitat Autònoma de Barcelona), Roser Pujol(Universitat Autònoma de Barcelona), Brita Arver(Karolinska University Hospital), Paolo Radice(IFOM), Åke Borg(Lund University), Rita K. Schmutzler(The University of Melbourne), Giovanna De Vecchi(IFOM), Kerstin Rhiem(University Hospital Cologne), Karin Wallander(Karolinska University Hospital)
Cited by 93
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Regulation of the Germinal Center Response by MicroRNA-155
|Science|2007|1.5k
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
|The American Journal of Human Genetics|2018|1.2k
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
|Nature Genetics|2013|1.1k